Liminal BioSciences Inc. PFSCF

RE:stockbaboon, thats what i've always said, voucher is on

[GunnerG]

LOL, that is how the FDA releases the voucher you dolt.  No one cares what you have to say.

Da rules of FDA.  "I've always said..." ROFLMAO

realstocky wrote:

upon FDA ok! And we also agree on the value of the voucher +- 100M$ which 70% goes to LMNL! See we can all be friends... as for the inspection of the facility, i double Kedrion would of made that deal if it wasnt done or of it didnt think we would get the green light... we will soon know bud:) The more friends the better... xx ( on the cheek ):)

 

we're getting about 100M$ first week of june...

market cap is around that at the moment. Think about it means sp wise, and buy your shares if u see it. Next is pbi4050 that they will partner... thats worth 10x more than riplazym....

 

i have no problem buying at these levels and holding until the first week of june. I estimate the risk low as FDA already reviewed riplazym and it was no problem, only asked for more check points. We're at stage to place your bets, big players did 2  days ago where the sp hit near 5$, first week of june trading could be 10 to 15$...on FDA  ok....

FDA granted ALREADY ORPHAN STATUS to riplazym... voucher with FDA ok will be worth around 120M$ automatically 1st week of june....we get 70% of that, Kedrion takes care of everything else, commercialisation, expenses etc,

+17M +5M, total value of deal is  more than 100M$ to LMNL. (NR yesterday)

106M$ inflows to LMNL...

As usual do your dd. Dont listen to anyone on stockhouse boards.

 

 

Through its’ US subsidiary, Prometic Biotherapeutics Inc., the Company has resubmitted a BLA in September 2020 with the FDA seeking approval to treat patients with C-PLGD. The FDA confirmed that the resubmission is a complete, Class 2 response to the complete response letter issued in 2018 and has provided a Prescription Drug User Fee Act (“PDUFA”) target action date of June 5, 2021.

Ryplazim® has previously been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for the treatment of congenital plasminogen deficiency. ====>voucher:)

--------------------------------------

https://www.marketbeat.com/stocks/NASDAQ/LMNL/price-target/

 

LMNL Consensus Rating:	Hold	Hold	Hold	Hold
LMNL Consensus Rating Score:	2.20	2.25	2.33	2.00
LMNL Analyst Ratings:	1 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
LMNL Consensus Price Target:	$18.00	$18.00	$21.50	$21.00
LMNL Price Target Upside:	333.73% upside	283.39% upside	425.67% upside	N/A

 

----------------------------------------------------------------------------------------------------------------------

 FDA already reviewed riplazym and it was no problem, only asked for aditional check points... i think this time we'll get it!  LMNL also hired a quality assurance specialist moira daniels, i bet to please the FDA.